Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“In contrast, the MTT incremental … curve (iAUC) for both glucose (from 249.3 ± 28.5 to 198.8 ± 23.6 mmol/L ⋅ min, P < 0.01) and insulin (from … [13,542–35,292] to 13,086 [9,804–21,138] pmol/L ⋅ min, P < 0.05) decreased with colesevelam.”
“CONCLUSION When added to metformin-including therapy, co esevelam HC l significantly reduced A1C and fas ting glucose, a s well as levels of LDL-C, TC, non-HDL-C, and apo B in patients with inadequately controlled T2DM.”
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists • 2011 | View Paper
“ResultsCompared with placebo, colesevelam improved HbA1c (mean change from baseline of 0.3 [SD 1.1]% for placebo [n = 28] and −0.3 [1.1]% for colesevelam [n = 26]), glucose concentrations, fasting plasma glucose clearance and glycolytic disposal of oral glucose.”
“The postprandial … for glucose … colesevelam versus placebo at weeks 2 and 8 with last observation carried forward (P = 0.012 and P = 0.061, respectively); the area … insulin did not decrease in concert with the decrease in area under the curve for glucose at week 2 (P = 0.585).”
Metabolic syndrome and related disorders • 2010 | View Paper
“Here, we demonstrate that the bile acid sequestrant, colesevelam , significantly reduced hepatic glucose production by suppressing hepatic glycogenolysis in diet-induced obese mice and that this was partially mediated by activation of the G protein-coupled bile acid receptor TGR5 and glucagon-like peptide-1 (GLP-1) release.”